S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
These cryptos could skyrocket by January (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
These cryptos could skyrocket by January (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
These cryptos could skyrocket by January (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
These cryptos could skyrocket by January (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage

Lionheart Acquisition Co. II (LCAP) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

LCAP vs. EVAX, MBOT, XLO, AGE, TLIS, VBIV, PAVM, NNVC, TFFP, and RNXT

Should you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Evaxion Biotech A/S (EVAX), Microbot Medical (MBOT), Xilio Therapeutics (XLO), AgeX Therapeutics (AGE), Talis Biomedical (TLIS), VBI Vaccines (VBIV), PAVmed (PAVM), NanoViricides (NNVC), TFF Pharmaceuticals (TFFP), and RenovoRx (RNXT). These companies are all part of the "medical" sector.

Lionheart Acquisition Co. II vs.

Lionheart Acquisition Co. II (NASDAQ:LCAP) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.

Evaxion Biotech A/S received 14 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users.

CompanyUnderperformOutperform
Lionheart Acquisition Co. IIN/AN/A
Evaxion Biotech A/SOutperform Votes
14
51.85%
Underperform Votes
13
48.15%

0.6% of Evaxion Biotech A/S shares are owned by institutional investors. 19.4% of Lionheart Acquisition Co. II shares are owned by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evaxion Biotech A/S had 4 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 4 mentions for Evaxion Biotech A/S and 0 mentions for Lionheart Acquisition Co. II. Evaxion Biotech A/S's average media sentiment score of 0.68 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Evaxion Biotech A/S is being referred to more favorably in the news media.

Company Overall Sentiment
Lionheart Acquisition Co. II Neutral
Evaxion Biotech A/S Positive

Evaxion Biotech A/S has a consensus price target of $42.00, indicating a potential upside of 1,011.11%. Given Evaxion Biotech A/S's higher probable upside, analysts clearly believe Evaxion Biotech A/S is more favorable than Lionheart Acquisition Co. II.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lionheart Acquisition Co. II
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Evaxion Biotech A/S
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lionheart Acquisition Co. IIN/AN/A$3.21MN/AN/A
Evaxion Biotech A/SN/AN/A-$23.17M-$9.50-0.40

Lionheart Acquisition Co. II's return on equity of -44.30% beat Evaxion Biotech A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Lionheart Acquisition Co. IIN/A -44.30% 1.39%
Evaxion Biotech A/S N/A -451.63%-126.22%

Summary

Evaxion Biotech A/S beats Lionheart Acquisition Co. II on 7 of the 10 factors compared between the two stocks.


Get Lionheart Acquisition Co. II News Delivered to You Automatically

Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LCAP vs. The Competition

MetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ Exchange
Market Cap$14.79M$1.02B$4.82B$7.46B
Dividend YieldN/A5.11%5.40%3.86%
P/E RatioN/A592.97243.8518.28
Price / SalesN/A116.073,035.4468.54
Price / Cash20.6421.8590.7154.77
Price / Book-0.282.334.384.77
Net Income$3.21M-$7.68M$108.96M$205.13M

Lionheart Acquisition Co. II Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVAX
Evaxion Biotech A/S
2.5597 of 5 stars
$3.99
-1.5%
$42.00
+952.6%
-75.3%$15.12MN/A-0.4263Positive News
Gap Up
MBOT
Microbot Medical
2.212 of 5 stars
$1.26
-2.3%
$8.00
+534.9%
-51.7%$15.10MN/A-1.0518
XLO
Xilio Therapeutics
0.9553 of 5 stars
$0.55
-9.8%
N/A-83.4%$15.18MN/A-0.1981Gap Up
AGE
AgeX Therapeutics
0 of 5 stars
$0.40
+2.6%
N/A-38.1%$15.07M$30,000.00-1.075Gap Up
TLIS
Talis Biomedical
0.1082 of 5 stars
$8.41
+1.0%
$5.00
-40.5%
+2.3%$15.31M$4.81M-0.20102Gap Down
VBIV
VBI Vaccines
0.7519 of 5 stars
$0.63
-3.1%
N/A-93.7%$14.93M$1.08M-0.05190Gap Up
PAVM
PAVmed
3.9112 of 5 stars
$1.92
-12.7%
$21.00
+993.8%
-70.6%$15.46M$380,000.00-0.18124News Coverage
NNVC
NanoViricides
0 of 5 stars
$1.25
+1.6%
$5.25
+318.8%
+5.6%$14.77MN/A-1.557Gap Up
TFFP
TFF Pharmaceuticals
1.6388 of 5 stars
$6.54
-5.8%
$137.50
+2,002.4%
-71.0%$15.50M$500,000.000.0015Upcoming Earnings
RNXT
RenovoRx
2.223 of 5 stars
$1.38
flat
$8.50
+515.9%
-62.4%$14.75MN/A-1.4710Gap Up

Related Companies and Tools

This page (NASDAQ:LCAP) was last updated on 2/26/2024 by MarketBeat.com Staff